Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX-474 in Healthy Adults
NCT06535841Phase 1Completed
- Sponsor
- Mediar Therapeutics
- Start
- Jul 2024
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MTX-474 in systemic sclerosis (SSc) (4 arms), sponsored by Mediar Therapeutics. Primary endpoints: Incidence of Treatment-Related Adverse Events at Day 50, Maximum Observed Serum Concentration at Day 50 and 2 more. Started Jul 2024; status: completed.
02
Drugs
MTX-474
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06535841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06535841.